Cargando…

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice

The most frequent site of recurrence in breast cancer (BC) is the bone, particularly in patients with ‘luminal-like’ disease. Denosumab has been shown to prevent aromatase inhibitors (AIs) induced bone resorption in postmenopausal early BC patients and reduce skeletal-related events (SREs) in bone m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortellini, Alessio, Cocciolone, Valentina, Irelli, Azzurra, Pavese, Francesco, Sidoni, Tina, Parisi, Alessandro, Lanfiuti Baldi, Paola, Venditti, Olga, D'Orazio, Carla, Bonfili, Pierluigi, Franzese, Pietro, Zugaro, Luigi, Verna, Lucilla, Porzio, Giampiero, Santini, Daniele, Cannita, Katia, Ficorella, Corrado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256706/ https://www.ncbi.nlm.nih.gov/pubmed/30546457 http://dx.doi.org/10.3892/ol.2018.9561

Ejemplares similares

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy
por: Cortellini, Alessio, et al.
Publicado: (2017)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis
por: Cocciolone, Valentina, et al.
Publicado: (2017)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)

Cancer Care After Natural Disaster: Different Countries, Similar Problems
por: Verna, Lucilla, et al.
Publicado: (2019)

Single‐institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non‐small cell lung cancer patients treated with first‐line chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2018)

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report
por: Cortellini, Alessio, et al.
Publicado: (2019)

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations
por: Cocciolone, Valentina, et al.
Publicado: (2018)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
por: Irelli, Azzurra, et al.
Publicado: (2022)

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
por: Cortellini, Alessio, et al.
Publicado: (2020)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Physical Exercise and Quality of Life in Breast Cancer Survivors
por: VALENTI, Marco, et al.
Publicado: (2008)

What Is Known about Theragnostic Strategies in Colorectal Cancer
por: Parisi, Alessandro, et al.
Publicado: (2021)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future
por: Parisi, Alessandro, et al.
Publicado: (2020)

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity
por: Cianci, G, et al.
Publicado: (2003)

Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol
por: Porzio, Giampiero, et al.
Publicado: (2020)

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
por: Bruera, Gemma, et al.
Publicado: (2010)

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
por: Ficorella, C, et al.
Publicado: (2004)

Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2017)

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes
por: Zelli, Veronica, et al.
Publicado: (2020)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Family history of cancer and DNA damage response genes: Two sides of the same coin?
por: Cortellini, Alessio, et al.
Publicado: (2018)

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
por: Cortellini, Alessio, et al.
Publicado: (2020)

Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception
por: Irelli, Azzurra, et al.
Publicado: (2022)

Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
por: Irelli, Azzurra, et al.
Publicado: (2023)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021)

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

“Vessels in the Storm”: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer
por: Angelucci, Adriano, et al.
Publicado: (2018)

Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients
por: Di Staso, Mario, et al.
Publicado: (2015)

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
por: Parisi, Alessandro, et al.
Publicado: (2020)

Rare bone toxicity associated with vismodegib
por: Ciciarelli, Valeria, et al.
Publicado: (2020)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_754ij31tplcdcsrbrkbcrv0aqu